MediWound Enrolls First Patient in Phase 2 Pharmacology Study of EscharEx

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 8/22/2026

1. WMT
2. ROST
3. AAP
4. SPY
5. NVDA
6. AVGO
7. SPCX
8. DE
9. OSIS
10. REAX

Go back to MediWound Enrolls First Patient in Phase 2 Pharmacology Study of EscharEx
MEDIWOUND (NASDAQ: MDWD) Delayed: 13.21 +0.09 (0.69%)
Previous Close $13.12    52 Week High $10.47 
Open $13.15    52 Week Low $5.10 
Day High $13.32    P/E N/A 
Day Low $13.07    EPS $0.00 
Volume 79,832